Sobi and Sanofi’s Foundation S renew partnership with World Federation of Hemophilia
Ella Day | April 28, 2025 | News story | Pharmacy sales & educational programmes, Sales and Marketing | Haematology, Sanofi, World Federation of Hemophilia, bleeding disorder, sobi
Sobi and Sanofi, through its organisation Foundation S, have extended their partnership with the World Federation of Hemophilia (WFH) Humanitarian Aid Program for another five years. The biopharma companies will continue to support the programme’s operations, advancing the WFH’s mission of improving inherited bleeding disorder treatment globally.
Specifically, Sobi and Sanofi will donate up to 100 million international units (IU) of factor therapy annually that will be distributed by the WFH to developing countries, where treatment is less accessible on average.
The partnership has been in place over the last decade and the renewal coincides with the tenth anniversary of the collaboration. Between 2014 and 2024, Sanofi and Sobi provided one billion IUs of treatment product, allowing for 22,219 people with inherited bleeding disorders to be treated.
“Over the past decade, these contributions have expanded treatment availability and transformed patient outcomes,” said head of medical affairs at Sanofi, Alaa Hamed.
Sobi’s head of R&D and CMO, Lydia Abad-French, commented: “We are thrilled to continue our partnership with the WFH and look forward to the positive impact it will have on the lives of those affected by inherited bleeding disorders.”
Mark Skinner, board member of WFH reflected on the partnership: “The WFH Humanitarian Aid Program is an extraordinary example of collaboration. The life-changing impact is a testament to what can be achieved by working together with our industry partners.”
Ella Day
28/4/25
Related Content
Excellence in Healthcare Partnership Awards – A Collaborative Working Project Between Sanofi and The University Hospital Birmingham Severe Asthma Team
Launched in February 2026 by PMGroup Worldwide Ltd and Visions4Health, the Excellence in Healthcare Partnerships …
Sobi’s Aspaveli receives European Commission approval for treatment of two rare kidney diseases
Sobi has announced that its Aspaveli (pegcetacoplan) has received approval from the European Commission (EC) …
Mavatar announces research collaboration with Sobi
Mavatar has announced the initiation of a non-clinical research collaboration with Sobi, using Mavatar’s technology …
